Related references
Note: Only part of the references are listed.Dissociable changes in spike and wave discharges following exposure to injected cannabinoids and smoked cannabis in Genetic Absence Epilepsy Rats from Strasbourg
Andrew J. Roebuck et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2022)
New and emerging pharmacologic treatments for developmental and epileptic encephalopathies
Alejandra Vasquez et al.
CURRENT OPINION IN NEUROLOGY (2022)
Cannabidiol Increases Seizure Resistance and Improves Behavior in an Scn8a Mouse Model
Lindsey Shapiro et al.
FRONTIERS IN PHARMACOLOGY (2022)
Anticonvulsive properties of soticlestat, a novel cholesterol 24-hydroxylase inhibitor
Toshiya Nishi et al.
EPILEPSIA (2022)
Is cannabidiol worth a trial in Rasmussen encephalitis?
Christine Prager et al.
EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY (2022)
Can Old Animals Reveal New Targets? The Aging and Degenerating Brain as a New Precision Medicine Opportunity for Epilepsy
Aaron del Pozo et al.
FRONTIERS IN NEUROLOGY (2022)
Effects of chronic cannabidiol in a mouse model of naturally occurring neuroinflammation, neurodegeneration, and spontaneous seizures
Joshua T. Dearborn et al.
SCIENTIFIC REPORTS (2022)
Anticonvulsant Action and Long-Term Effects of Chronic Cannabidiol Treatment in the Rat Pentylenetetrazole-Kindling Model of Epilepsy
Zsolt Gall et al.
BIOMEDICINES (2022)
Cannabidiol reduces soman-induced lethality and seizure severity in female plasma carboxylesterase knockout mice treated with midazolam
Erica R. Kundrick et al.
NEUROTOXICOLOGY (2021)
Cannabidiol in the treatment of epilepsy: Current evidence and perspectives for further research
Valentina Franco et al.
NEUROPHARMACOLOGY (2021)
Development of an antiseizure drug screening platform for Dravet syndrome at the NINDS contract site for the Epilepsy Therapy Screening Program
Chelsea D. Pernici et al.
EPILEPSIA (2021)
Antiseizure effects of the cannabinoids in the amygdala-kindling model
Merrick S. Fallah et al.
EPILEPSIA (2021)
Time to onset of cannabidiol treatment effects in Dravet syndrome: Analysis from two randomized controlled trials
Jennifer Madan Cohen et al.
EPILEPSIA (2021)
Soticlestat, a novel cholesterol 24-hydroxylase inhibitor, reduces seizures and premature death in Dravet syndrome mice
Nicole A. Hawkins et al.
EPILEPSIA (2021)
The current approach of the Epilepsy Therapy Screening Program contract site for identifying improved therapies for the treatment of pharmacoresistant seizures in epilepsy
Karen S. Wilcox et al.
NEUROPHARMACOLOGY (2020)
Cannabidiol improves survival and behavioural co-morbidities of Dravet syndrome in mice
Pabitra Hriday Patra et al.
BRITISH JOURNAL OF PHARMACOLOGY (2020)
Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome A Randomized Clinical Trial
Ian Miller et al.
JAMA NEUROLOGY (2020)
Mechanisms of action of currently used antiseizure drugs
Graeme J. Sills et al.
NEUROPHARMACOLOGY (2020)
Interactions between cannabidiol and Δ9-tetrahydrocannabinol in modulating seizure susceptibility and survival in a mouse model of Dravet syndrome
Lyndsey L. Anderson et al.
BRITISH JOURNAL OF PHARMACOLOGY (2020)
Soticlestat, a novel cholesterol 24-hydroxylase inhibitor shows a therapeutic potential for neural hyperexcitation in mice
Toshiya Nishi et al.
SCIENTIFIC REPORTS (2020)
Cannabidiol-Enriched Extract Reduced the Cognitive Impairment but Not the Epileptic Seizures in a Lafora Disease Animal Model
Ester Aso et al.
CANNABIS AND CANNABINOID RESEARCH (2020)
Anticonvulsive Properties of Cannabidiol in a Model of Generalized Seizure Are Transient Receptor Potential Vanilloid 1 Dependent
Royston A. Gray et al.
CANNABIS AND CANNABINOID RESEARCH (2020)
Progress report on new antiepileptic drugs: A summary of the Fifteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XV). I. Drugs in preclinical and early clinical development
Meir Bialer et al.
EPILEPSIA (2020)
Progress report on new antiepileptic drugs: A summary of the Fifteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XV). II. Drugs in more advanced clinical development
Meir Bialer et al.
EPILEPSIA (2020)
A Phase 1, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics and Safety of Cannabidiol (CBD) in Subjects With Mild to Severe Hepatic Impairment
Lesley Taylor et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Targeting oxidative stress improves disease outcomes in a rat model of acquired epilepsy
Alberto Pauletti et al.
BRAIN (2019)
Cannabidiol attenuates seizures and EEG abnormalities in Angelman syndrome model mice
Bin Gu et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Acute effect of cannabidiol on the activity of various novel antiepileptic drugs in the maximal electroshock- and 6 Hz-induced seizures in mice: Pharmacodynamic and pharmacokinetic studies
Katarzyna Socala et al.
NEUROPHARMACOLOGY (2019)
Cannabidiol reduces seizures and associated behavioral comorbidities in a range of animal seizure and epilepsy models
Pabitra Hriday Patra et al.
EPILEPSIA (2019)
Long-term cannabidiol treatment in patients with Dravet syndrome: An open-label extension trial
Orrin Devinsky et al.
EPILEPSIA (2019)
Cannabidiol reduces seizures following CNS infection with Theiler's murine encephalomyelitis virus
Dipan C. Patel et al.
EPILEPSIA OPEN (2019)
Commonalities in epileptogenic processes from different acute brain insults: Do they translate?
Pavel Klein et al.
EPILEPSIA (2018)
Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial
Elizabeth A. Thiele et al.
LANCET (2018)
Macrophage depletion by liposome-encapsulated clodronate suppresses seizures but not hippocampal damage after acute viral encephalitis
Inken Waltl et al.
NEUROBIOLOGY OF DISEASE (2018)
Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome
Orrin Devinsky et al.
NEUROLOGY (2018)
Treatment Outcomes in Patients With Newly Diagnosed Epilepsy Treated With Established and New Antiepileptic Drugs A 30-Year Longitudinal Cohort Study
Zhibin Chen et al.
JAMA NEUROLOGY (2018)
A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans
Sophie A. Millar et al.
FRONTIERS IN PHARMACOLOGY (2018)
Cannabidiol as a Potential Treatment for Febrile Infection-Related Epilepsy Syndrome (FIRES) in the Acute and Chronic Phases
Jacqueline S. Gofshteyn et al.
JOURNAL OF CHILD NEUROLOGY (2017)
The Search for New Screening Models of Pharmacoresistant Epilepsy: Is Induction of Acute Seizures in Epileptic Rodents a Suitable Approach?
Wolfgang Loescher
NEUROCHEMICAL RESEARCH (2017)
Neuroinflammation in epileptogenesis: Insights and translational perspectives from new models of epilepsy
Melissa L. Barker-Haliski et al.
EPILEPSIA (2017)
Anticonvulsant effect of cannabidiol in the pentylenetetrazole model: Pharmacological mechanisms, electroencephalographic profile, and brain cytokine levels
Luciano R. Vilela et al.
EPILEPSY & BEHAVIOR (2017)
Scavenging reactive oxygen species inhibits status epilepticus-induced neuroinflammation
Pallavi B. McElroy et al.
EXPERIMENTAL NEUROLOGY (2017)
Blockade of the IL-1R1/TLR4 pathway mediates disease-modification therapeutic effects in a model of acquired epilepsy
Valentina Iori et al.
NEUROBIOLOGY OF DISEASE (2017)
Animal Models of Seizures and Epilepsy: Past, Present, and Future Role for the Discovery of Antiseizure Drugs
Wolfgang Loscher
NEUROCHEMICAL RESEARCH (2017)
Evaluation of Cannabidiol in Animal Seizure Models by the Epilepsy Therapy Screening Program (ETSP)
Brian D. Klein et al.
NEUROCHEMICAL RESEARCH (2017)
The National Institute of Neurological Disorders and Stroke (NINDS) Epilepsy Therapy Screening Program (ETSP)
John H. Kehne et al.
NEUROCHEMICAL RESEARCH (2017)
Validation of a Preclinical Drug Screening Platform for Pharmacoresistant Epilepsy
Melissa L. Barker-Haliski et al.
NEUROCHEMICAL RESEARCH (2017)
Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome
Rongrui Tang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome
Orrin Devinsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome
Joshua S. Kaplan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Protective Effects of Cannabidiol against Seizures and Neuronal Death in a Rat Model of Mesial Temporal Lobe Epilepsy
Raquel A. Do Val-da Silva et al.
FRONTIERS IN PHARMACOLOGY (2017)
Aberrant epilepsy-associated mutant Nav1.6 sodium channel activity can be targeted with cannabidiol
Reesha R. Patel et al.
BRAIN (2016)
Acute treatment with minocycline, but not valproic acid, improves long-term behavioral outcomes in the Theiler's virus model of temporal lobe epilepsy
Melissa L. Barker-Haliski et al.
EPILEPSIA (2016)
Fit for purpose application of currently existing animal models in the discovery of novel epilepsy therapies
Wolfgang Loescher
EPILEPSY RESEARCH (2016)
Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial
Orrin Devinsky et al.
LANCET NEUROLOGY (2016)
2014 Epilepsy Benchmarks Area II: Prevent Epilepsy and Its Progression
Aristea S. Galanopoulou et al.
Epilepsy Currents (2016)
Disease Modification in Epilepsy: From Animal Models to Clinical Applications
Melissa L. Barker-Haliski et al.
DRUGS (2015)
Validation of the 6 Hz refractory seizure mouse model for intracerebroventricularly administered compounds
Laura Walrave et al.
EPILEPSY RESEARCH (2015)
JAK/STAT pathway regulation of GABAA receptor expression after differing severities of experimental TBI
Daniel J. Raible et al.
EXPERIMENTAL NEUROLOGY (2015)
Pathogenesis and new candidate treatments for infantile spasms and early life epileptic encephalopathies: A view from preclinical studies
Aristea S. Galanopoulou et al.
NEUROBIOLOGY OF DISEASE (2015)
Cannabinoids and Epilepsy
Evan C. Rosenberg et al.
NEUROTHERAPEUTICS (2015)
Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism
T. D. M. Hill et al.
BRITISH JOURNAL OF PHARMACOLOGY (2013)
Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy
Brenda E. Porter et al.
EPILEPSY & BEHAVIOR (2013)
Sudden unexpected death in a mouse model of Dravet syndrome
Franck Kalume et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Infiltrating Macrophages Are Key to the Development of Seizures following Virus Infection
Matthew F. Cusick et al.
JOURNAL OF VIROLOGY (2013)
New avenues for anti-epileptic drug discovery and development
Wolfgang Loescher et al.
NATURE REVIEWS DRUG DISCOVERY (2013)
Glia and epilepsy: excitability and inflammation
Orrin Devinsky et al.
TRENDS IN NEUROSCIENCES (2013)
Drug screening in Scn1a zebrafish mutant identifies clemizole as a potential Dravet syndrome treatment
Scott C. Baraban et al.
NATURE COMMUNICATIONS (2013)
Cannabidivarin is anticonvulsant in mouse and rat
A. J. Hill et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Inverse relationship of cannabimimetic (R+)WIN 55, 212 on behavior and seizure threshold during the juvenile period
V. Rudenko et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2012)
Specific deletion of NaV1.1 sodium channels in inhibitory interneurons causes seizures and premature death in a mouse model of Dravet syndrome
Christine S. Cheah et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ9-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour
Serena Deiana et al.
PSYCHOPHARMACOLOGY (2012)
Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures
Nicholas A. Jones et al.
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY (2012)
Dravet syndrome: The long-term outcome
Pierre Genton et al.
EPILEPSIA (2011)
Interleukin-6, Produced by Resident Cells of the Central Nervous System and Infiltrating Cells, Contributes to the Development of Seizures following Viral Infection
Jane E. Libbey et al.
JOURNAL OF VIROLOGY (2011)
Inflammation induced by LPS enhances epileptogenesis in immature rat and may be partially reversed by IL1RA
Stephane Auvin et al.
EPILEPSIA (2010)
Innate but not adaptive immune responses contribute to behavioral seizures following viral infection
Nikki J. Kirkman et al.
EPILEPSIA (2010)
Cannabidiol Displays Antiepileptiform and Antiseizure Properties In Vitro and In Vivo
Nicholas A. Jones et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2010)
NaV1.1 channels and epilepsy
William A. Catterall et al.
JOURNAL OF PHYSIOLOGY-LONDON (2010)
Inflammation enhances epileptogenesis in the developing rat brain
Stephane Auvin et al.
NEUROBIOLOGY OF DISEASE (2010)
Anticonvulsant and Antiepileptic Actions of 2-Deoxy-D-Glucose in Epilepsy Models
Carl E. Stafstrom et al.
ANNALS OF NEUROLOGY (2009)
Seizures following picornavirus infection
Jane E. Libbey et al.
EPILEPSIA (2008)
Nav1.1 localizes to axons of parvalbumin-positive inhibitory interneurons:: A circuit basis for epileptic seizures in mice carrying an Scn1a gene mutation
Ikuo Ogiwara et al.
JOURNAL OF NEUROSCIENCE (2007)
Kindling epileptogenesis in immature rats leads to persistent depressive behavior
Andrey Mazarati et al.
EPILEPSY & BEHAVIOR (2007)
Prevention of plasticity of endocannabinoid signaling inhibits persistent limbic hyperexcitability caused by developmental seizures
Kang Chen et al.
JOURNAL OF NEUROSCIENCE (2007)
Cannabinoid pharmacology: the first 66 years
RG Pertwee
BRITISH JOURNAL OF PHARMACOLOGY (2006)
Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy
Frank H. Yu et al.
NATURE NEUROSCIENCE (2006)
A common ankyrin-G-based mechanism retains KCNQ and NaV channels at electrically active domains of the axon
ZM Pan et al.
JOURNAL OF NEUROSCIENCE (2006)
CB1 cannabinoid receptors and on-demand defense against excitotoxicity
G Marsicano et al.
SCIENCE (2003)
De Novo SCN1A mutations are a major cause of severe myoclonic epilepsy of infancy
L Claes et al.
HUMAN MUTATION (2003)
Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy
ME Barton et al.
EPILEPSY RESEARCH (2001)
Share Paper
